Clinical trial
A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
NCT05123534 is registered in ClinicalTrials.gov with SonALAsense, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
- Lead sponsor
- SonALAsense, Inc.
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- August 12, 2022
- Completion date
- October 30, 2024
- Enrollment
- 15 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse intrinsic pontine glioma, diffuse midline glioma